跳至主要内容
临床试验/NCT06372106
NCT06372106招募中不适用

Philips FAST picoSAT Convenience Sampling for Clinical Performance in Neonate, Infant, and Pediatric Patients

Philips Clinical & Medical Affairs Global5 个研究点 分布在 1 个国家目标入组 560 人开始时间: 2024年4月4日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
560
试验地点
5
主要终点
To observed accuracy expressed in ARMS of SpO2 measurements obtained from neonatal, infant, and pediatric sensors with the Philips FAST Pulse Oximetry technology within the range of 70-100% in comparison to the SaO2 as ground truth.

研究概览

简要总结

The main goal of this study is to look at the performance of the neonatal, infant, and pediatric Philips SpO2 sensors with the Philips FAST Pulse Oximetry technology. Oxygen saturation measurements (SpO2) will be obtained via pulse oximetry and invasive arterial oxygen measurements (SaO2) will be obtained via arterial blood samples as part of your clinical care and assessed by co-oximetry. The study will aim to enroll a diverse population to help us understand the impact of skin pigmentation.

详细描述

This is a prospective, multi-center, multi-phase, unblinded, non-randomized. self-controlled, observational study. All data analyses specified below will be calculated and summarized by each of SpO2 sensors under test. Demographics and baseline characteristics, including sex assigned at birth, age, ethnicity, race, baseline height, baseline weight, BMI, skin pigmentation and sensor application site measurements will be summarized with descriptive statistics using the analysis set.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Other

入排标准

性别
All
接受健康志愿者

入选标准

  • Subject aged 18 years or older or parent/legal guardian of subject aged less than 18 years, willing and able to understand and provide written informed consent/assent.
  • Weight and/or age within intended use of at least one SpO2 sensor under test at time of enrollment.
  • Willing and able to wear study devices in addition to SoC devices and during SoC procedures.
  • In-patient within a neonatal or pediatric intensive care unit (e.g. NICU, PICU, PCICU).
  • Has arterial access and ability to have arterial blood samples drawn as part of their SoC and analyzed by CO-Oximetry.

排除标准

  • Known pregnancy or lactating females (self-reported)
  • Injury, wounds, physical malformation, hyperkeratosis, or compromised/non-intact skin at sensor application site (i.e. fingers, toes, hands, feet, ears, nasal ala). Note: Certain malformations may be allowed if determined it would not affect application of sensor with the pulse oximetry system.
  • Self-reported severe contact allergies to standard adhesives or other materials found in pulse oximetry sensors. Note: Subject may be considered eligible if subject can wear non-adhesive sensor.
  • Unwillingness or inability to remove nail polish or artificial nails from sensor application site.
  • Nail fungus on sensor application site.
  • Wearing and unable to remove jewelry from sensor application site.
  • Dye injection within 48 hours of enrollment.
  • Known dysfunctional hemoglobin levels (COHb >3%, MetHb >2%, and ctHb <10g/dl)
  • Undergoing phototherapy for neonatal hyperbilirubinemia during arterial blood sampling

结局指标

主要结局

To observed accuracy expressed in ARMS of SpO2 measurements obtained from neonatal, infant, and pediatric sensors with the Philips FAST Pulse Oximetry technology within the range of 70-100% in comparison to the SaO2 as ground truth.

时间窗: through study completion, an average of 8 months

The oximetry technology will be expressed in ARMS of SpO2 measurements obtained from neonatal, infant, and pediatric sensors with the Philips FAST Pulse Oximetry technology within the range of 70-100% in comparison to the SaO2 as ground truth.

次要结局

  • Secondary Endpoint -Non-disparate bias with consideration to skin pigmentation for each neonatal, infant, and pediatric SpO2 sensor under test with the Philips FAST Pulse Oximetry technology.(through study completion, an average of 8 months)
  • Secondary Endpoint- Proportion of paired SaO2 and SpO2 readings in which occult hypoxemia (i.e., SaO2 <88% with SpO2 ≥92%) is identified among patients within the broad categories of light, medium, and dark pigmentation.(through study completion, an average of 8 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验